KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Receivables - Other (2020 - 2021)

Historic Receivables - Other for AbCellera Biologics (ABCL) over the last 2 years, with Q2 2021 value amounting to $62.1 million.

  • AbCellera Biologics' Receivables - Other changed N/A to $62.1 million in Q2 2021 from the same period last year, while for Jun 2021 it was $62.1 million, marking a year-over-year change of. This contributed to the annual value of $212.3 million for FY2020, which is N/A changed from last year.
  • Per AbCellera Biologics' latest filing, its Receivables - Other stood at $62.1 million for Q2 2021.
  • AbCellera Biologics' Receivables - Other's 5-year high stood at $212.3 million during Q4 2020, with a 5-year trough of $62.1 million in Q2 2021.